FC
EXAS

Farringdon Capital’s Exact Sciences EXAS Stock Holding History

Farringdon Capital’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,933
Closed -$215K – 490
2025
Q3 		$215K Buy
+3,933
New +$197K 0.05% 387

Other funds holding EXAS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Farringdon Capital's EXAS Position: Q4 2025 in Review

Farringdon Capital sold out of Exact Sciences (EXAS) in Q4 2025, closing a stake of 3,933 shares — an estimated $215K sold.

Farringdon Capital first reported a position in EXAS in Q3 2025 and held it in 1 quarter. The position peaked at $215K in Q3 2025. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.

  • Farringdon Capital reported no remaining Exact Sciences position as of Q4 2025 after selling out during the quarter.
  • Farringdon Capital sold 3,933 Exact Sciences shares in Q4 2025, an estimated $215K.
  • Farringdon Capital first reported a position in Exact Sciences in Q3 2025 and held it in 1 quarter.
  • Farringdon Capital's Exact Sciences position peaked at $215K in Q3 2025.
  • 711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.

Based on Farringdon Capital's 13F filing for Q4 2025, filed 17 Feb 2026.